Knowledge of CYP2C9 and VKORC1 genotype can improve dosing of warfarin.

被引：0
|
作者：
Kim, M.
Huang, S.
Frueh, F.
Rahman, A.
Burckart, G. J.
Thummel, K. E.
Lesko, L. J.
机构：
[1] Univ So Calif, US FDA, Silver Spring, MD USA
[2] Washington Univ, US FDA, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [21] Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin
    Fung, Erik
    Patsopoulos, Nikolaos A.
    Belknap, Steven M.
    O'Rourke, Daniel J.
    Robb, John F.
    Anderson, Jeffrey L.
    Shworak, Nicholas W.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08): : 893 - 904
  • [22] Effect of CYP2C9 and VKORC1 genetic polymorphism on Warfarin dose requirement
    Ashavaid, T. F.
    Ponde, C. K.
    Raghavan, R.
    Kapadia, F. N.
    Shah, S. A.
    Natarajan, S.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 507 - 508
  • [23] The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians
    Bedewy, Ahmed M. L.
    Showeta, Salah
    Mostafa, Mostafa Hasan
    Kandil, Lamia Saeed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 328 - 336
  • [24] CYP2C9, VKORC1 AND CALU GENOTYPE FREQUENCIES IN THE NATIVE OMANI POPULATION
    Pathare, V.
    Al Zadjali, A.
    Alkindi, S.
    Al Farsi, S.
    Huneini, N.
    Dennison, J.
    Misquith, L.
    Krishnamoorthy, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 679 - 679
  • [25] VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children
    Biss, T. T.
    Avery, P. J.
    Williams, M. D.
    Brandao, L. R.
    Grainger, J. D.
    Leathart, J. B. S.
    Kamali, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 31 - 32
  • [26] Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
    Miao, Liyan
    Yang, Jian
    Huang, Chenrong
    Shen, Zhenya
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (12) : 1135 - 1141
  • [27] Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Scott, Stuart A.
    Patel, Manishkumar
    Martis, Suparna
    Lubitz, Steven A.
    van der Zee, Sarina
    Yoo, Chang
    Edelmann, Lisa
    Halperin, Jonathan L.
    Desnick, Robert J.
    PHARMACOGENOMICS, 2012, 13 (03) : 297 - 307
  • [28] Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
    Liyan Miao
    Jian Yang
    Chenrong Huang
    Zhenya Shen
    European Journal of Clinical Pharmacology, 2007, 63 : 1135 - 1141
  • [29] Inter-individual variability in warfarin dose requirement in children can be explained by VKORC1 and CYP2C9 genotype and patient characteristics
    Biss, T. T.
    Avery, P. J.
    Brandao, L. R.
    Chalmers, E. A.
    Williams, M. D.
    Grainger, J. D.
    Leathart, J. B. S.
    Hanley, J. P.
    Daly, A. K.
    Kamali, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 286 - 286
  • [30] Comparison of Three Commercial CYP2C9/VKORC1 Genotyping Assays for Warfarin Sensitivity
    Maurice, C. B.
    Barua, P. K.
    Simses, D.
    Smith, P.
    Howe, J. G.
    Stack, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 566 - 566
12345